11546 Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices 

Divided into two comprehensive 

activity categories: ‘‘State-level 

Activities’’ and ‘‘State Leadership 

Activities,’’ according to Section 4 of the 

AT Act, as a condition of receiving a 

grant to support their Statewide AT 

Programs, the 56 states and outlying 

areas must provide to ACL: (1) 

Applications and (2) annual progress 

reports on their activities. 

Applications: The application 

required of states and outlying areas is 

a three-year State Plan for Assistive 

Technology (State Plan for AT or State 

Plan) (OMB No. 0985–0048). The 

content of the State Plan for AT is based 

on the requirements in Section 4(d) of 

the AT Act. 

Annual Reports: In addition to 

submitting a State Plan, every three 

years, states and outlying areas are 

required to submit annual progress 

reports on their activities. The data 

required in that progress report is 

specified in Section 4(f) of the AT Act 

(OMB No. 0985–0042). 

National aggregation of data related to 

measurable goals is necessary for the 

Government Performance and Results 

Modernization Act of 2010 (GPRAMA) 

(Pub. L. 111–352), as well as an Annual 

Report to Congress (see ‘‘Section 7 

Requirements Necessitating Collection’’ 

below). Therefore, this data collection 

instrument provides a way for all 56 

grantees—50 U.S. states, DC, Puerto 

Rico, the U.S. Virgin Islands, Guam, 

American Samoa, and the 

Commonwealth of the Northern Mariana 

Islands to collect and report data on 

their activities in a consistent manner, 

including a uniform survey to be given 

to consumers. This uniform survey is 

included as part of the data collection 

package. 

Section 7(d) of the AT Act requires 

that ACL submit to Congress an annual 

report on the activities conducted under 

the Act and an analysis of the progress 

of the states and outlying areas in 

meeting their measurable goals. This 

report must include a compilation and 

summary of the data collected under 

Section 4(f). In order to make this 

possible, states and outlying areas must 

provide their data uniformly. This data 

collection instrument was developed to 

ensure that all 56 states and outlying 

areas report data in a consistent manner 

in alignment with the requirements of 

Section 4(f). 

As stated above, ACL will use the 

information collected via this 

instrument to: 

(1) Complete the annual report to 

Congress required by the AT Act; 

(2) Comply with reporting 

requirements under the Government 

Performance and Results Modernization 

Act of 2010 (GPRAMA) (Pub. L. 111– 

352); and 

(3) Assess the progress of states and 

outlying areas regarding measurable 

goals. Data collected from the grantees 

will provide a national description of 

activities funded under the AT Act to 

increase the access to and acquisition of 

AT devices and services through 

statewide AT programs for individuals 

with disabilities. Data collected from 

grantees will also provide information 

for usage by Congress, the Department, 

and the public. In addition, ACL will 

use this data to inform program 

management, monitoring, and technical 

assistance efforts. States will be able to 

use the data for internal management 

and program improvement. 

To review the proposed data 

collection tools please visit the ACL 

website at: https://www.acl.gov/aboutacl/public-input. 

Estimated Program Burden: ACL 

estimates the burden associated with 

this collection of information as follows: 

Respondent/data collection activity Number of 

respondents 

Responses 

per 

respondent 

Hours per 

response 

Annual burden 

hours 

State Plan for Assistive Technology ................................................................ 56 1 73.0 4,088 

Dated: February 19, 2021. 

Alison Barkoff, 

Acting Administrator and Assistant Secretary 

for Aging. 

[FR Doc. 2021–03868 Filed 2–24–21; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Peter Soukas, J.D., 301–594–8730; 

peter.soukas@nih.gov. Licensing 

information and copies of the patent 

applications listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD 20852; tel. 

301–496–2644. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Improved Live-Attenuated Vaccine for 

Respiratory Syncytial Virus (RSV) 

Bearing Codon-Pair Deoptimized NS1, 

NS2, N, P, M and SH Genes and 

Additional Point Mutations in the P 

Gene 

Description of Technology: 

RSV is the most important viral agent 

of severe respiratory disease in infants 

and young children worldwide and also 

causes substantial morbidity and 

mortality in older adults. RSV is 

estimated to cause more than 33 million 

lower respiratory tract illnesses, three 

million hospitalizations, and nearly 

200,000 childhood deaths worldwide 

annually, with many deaths occurring 

in developing countries. However, 

despite the prevalence of RSV and the 

dangers associated with infection, no 

RSV vaccine has been successfully 

developed to date. Accordingly, there is 

a public health need for RSV vaccines. 

This vaccine candidate comprises live 

RSV that was attenuated by subjecting 

the protein-coding sequences of the 

viral NS1, NS2, N, P, M, and SH genes 

to codon-pair deoptimization, which 

resulted in many nucleotide 

substitutions that were silent at the 

amino acid level but conferred 

attenuation. In addition, specific amino 

acid substitutions were identified and 

introduced into the P protein that 

improved attenuation and genetic 

stability. Genetic stability was 

confirmed in vitro, and attenuation was 

confirmed in experimental animals. 

Federal Register / Vol. 86, No. 36 / Thursday, February 25, 2021 / Notices 11547 

This live-attenuated RSV vaccine is 

designed to be administered intranasally 

by drops or spray to infants and young 

children. Based on experience with 

other live-attenuated RSV vaccine 

candidates, the present candidates are 

anticipated to be well tolerated in 

humans and are available for clinical 

evaluation. The National Institute of 

Allergy and Infectious Diseases has 

extensive experience and capability in 

evaluating live-attenuated RSV vaccine 

candidates in pediatric clinical studies, 

and opportunity for collaboration exists. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications: 

• Viral diagnostics 

• Vaccine research 

Competitive Advantages: 

• Ease of manufacture 

• B cell and T cell activation 

• Low-cost vaccines 

• Intranasal administration/needle-free 

delivery 

Development Stage: 

• In vivo data assessment (animal) 

Inventors: Cyril Le Nouen (NIAID), 

Ursula Buchholz (NIAID), Peter Collins 

(NIAID). 

Intellectual Property: HHS Reference 

No. E–104–2020–0—U.S. Provisional 

Application No. 63/023,949, filed May 

13, 2020. 

Licensing Contact: Peter Soukas, J.D., 

301–594–8730; peter.soukas@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize for development of a 

vaccine for respiratory or other 

infections. For collaboration 

opportunities, please contact Peter 

Soukas, J.D., 301–594–8730; 

peter.soukas@nih.gov. 

Dated: February 18, 2021. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2021–03872 Filed 2–24–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request; Generic Clearance 

To Support the Safe to Sleep®

Campaign at the Eunice Kennedy 

Shriver National Institute for Child 

Health and Human Development 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, the 

National Institutes of Health (NIH) has 

submitted to the Office of Management 

and Budget (OMB) a request for review 

and approval of the information 

collection listed below. 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 30-days of the date of this 

publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact: Lorena Kaplan, 

M.P.H., CHES, Office of 

Communications, Eunice Kennedy 

Shriver National Institute of Child 

Health and Human Development, 

National Institutes of Health, 31 Center 

Drive, Room 2A32, Bethesda, Maryland 

20892, or call non-toll free number (301) 

496–6670 or Email your request, 

including your address to 

lorena.kaplan@nih.gov. 

SUPPLEMENTARY INFORMATION: This 

proposed information collection was 

previously published in the Federal 

Register on December 11, 2020, page 

80123–80124 (85 FR 80123–80124) and 

allowed 60 days for public comment. No 

public comments were received. The 

purpose of this notice is to allow an 

additional 30 days for public comment. 

The Eunice Kennedy Shriver National 

Institute for Child Health and Human 

Development, National Institutes of 

Health, may not conduct or sponsor, 

and the respondent is not required to 

respond to, an information collection 

that has been extended, revised, or 

implemented on or after October 1, 

1995, unless it displays a currently valid 

OMB control number. 

In compliance with Section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. 

Proposed Collection: Generic 

Clearance to Support the Safe to Sleep®

Campaign at the Eunice Kennedy 

Shriver National Institute for Child 

Health and Human Development 

(NICHD), 0925–0701, exp., date 02/28/ 

2021, REVISION, Eunice Kennedy 

Shriver National Institute of Child 

Health and Human Development 

(NICHD), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: This is a request for a 

revision to a generic clearance used for 

submissions specific to the Eunice 

Kennedy Shriver National Institute of 

Child Health and Human Development 

(NICHD) Safe to Sleep® (STS) public 

education campaign. Submissions for 

the STS campaign will be used to assess 

the understanding and reach of STS 

campaign materials and messages, and 

to monitor and improve campaign 

activities such as training workshops 

and overall implementation. The 

purpose of this information collection is 

to monitor and modify campaign 

activities, to plan future campaign 

activities, to develop messages and 

materials, and to develop distribution 

and outreach strategies that are effective 

at communicating their message to bring 

about the intended response, awareness, 

and/or behavioral change for the target 

audiences. This generic clearance will 

enable the NICHD to: (1) More 

efficiently assess the implementation of 

campaign activities; (2) better 

understand the target audiences’ 

knowledge, attitudes, and beliefs toward 

STS messages and materials; (3) better 

understand how the campaign activities 

have influenced the target audiences’ 

behaviors and practices; and (4) monitor 

and improve activities such as trainings, 

materials, and messages. Having a way 

to gather feedback on the STS campaign 

activities is critical to assessing the 

reach and effect of campaign efforts. 

Data collected for the campaign can 

inform where future STS campaign 

resources can produce the most 

meaningful results. Data collected for 

the STS campaign generic clearance will 

be used by a number of audiences, 

including STS campaign staff, NICHD 

leadership, STS campaign collaborators,